SCHEMBL6957174

SCHEMBL6957174

C=CCOC(=O)N1CCN(c2ccc(-c3ccnc(Nc4cc(Cl)c(Cl)c(Cl)c4)n3)cn2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ZAP70 P43403 11/20 0.49
▸ PRKD3 O94806 2/20 0.47
▸ PRKCG P05129 2/20 0.47
▸ PRKCB P05771 2/20 0.47
▸ LCK P06239 2/20 0.47
▸ PRKCA P17252 2/20 0.47
▸ PRKCH P24723 2/20 0.47
▸ PRKCI P41743 2/20 0.47
▸ PRKCE Q02156 2/20 0.47
▸ PRKCQ Q04759 2/20 0.47
▸ PRKCZ Q05513 2/20 0.47
▸ PRKCD Q05655 2/20 0.47
▸ PRKD1 Q15139 2/20 0.47
▸ EGFR P00533 1/20 0.47
▸ SYK P43405 4/20 0.42
▸ DGAT1 O75907 1/20 0.40
▸ PIK3C3 Q8NEB9 1/20 0.40
▸ PGK1 P00558 1/20 0.39
▸ JAK2 O60674 1/20 0.39
▸ JAK1 P23458 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6944958 0.78 ZAP70 (0.69) ZAP70PRKD3PRKCGPRKCBLCK
SCHEMBL6955414 0.74 ZAP70 (0.55) ZAP70PRKD3PRKCGPRKCBLCK
SCHEMBL8145178 0.71 HDAC1 (0.46) ZAP70PRKD3PRKCGPRKCBLCK
SCHEMBL8139918 0.69 SYK (0.46) ZAP70PRKD3PRKCGPRKCBLCK
SCHEMBL8148183 0.68 HDAC1 (0.53) DGAT1MEN1KMT2A
SCHEMBL8153192 0.68 BRAF (0.46) ZAP70PRKD3PRKCGPRKCBLCK
SCHEMBL6957131 0.68 ZAP70 (0.62) ZAP70PRKD3PRKCGPRKCBLCK
SCHEMBL8148529 0.67 BRAF (0.45) ZAP70PRKD3PRKCGPRKCBLCK
SCHEMBL8148421 0.67 WNT3A (0.49) ZAP70PRKD3PRKCGPRKCBLCK
SCHEMBL8148420 0.67 WNT3A (0.49) ZAP70PRKD3PRKCGPRKCBLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6552029-B1 For therapy of rheumatoid arthritis, psoriasis, graft v. host disease, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, complications following percutaneous transluminal coronary angioplasty, thrombosis CELLTECH R&D LIMITED (GB) 2003-04-22 — — US disclosed
EP-0934304-B1 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION CELLTECH THERAPEUTICS LTD (GB) 2003-02-26 — — EP disclosed
US-6114333-A 2-Pyrimidineamine derivatives and processes for their preparation CELLTECH THERAPEUTICS LTD. (GB) 2000-09-05 — — US disclosed
EP-0934304-A1 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION CELLTECH THERAPEUTICS LIMITED (GB) 1999-08-11 — — EP disclosed
WO-1998018782-A1 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION CELLTECH THERAPEUTICS LIMITED (GB) 1998-05-07 — — WO disclosed
Send feedback